Due to the potential relationship between NGAL levels and obesity-related metabolic complications, we also evaluated cystatin C, another biomarker of kidney function, in obese patients with type 2 diabetes and subjects with MHO. This evidence concerns the gene LCN2 and type 2 diabetes mellitus.